Stoke Therapeutics' Price Target Cut to $28 by BTIG Analyst Shrader

BTIG analyst Thomas Shrader lowered Stoke Therapeutics' price target to $28 from $29 and maintains a Buy rating. Shrader notes the company's 36-month data for Zorevunersen demonstrates impressive seizure reductions, even for patients who started with sub-optimal loading doses. The analyst sees this as a strong endorsement of the treatment's efficacy.

BTIG analyst Thomas Shrader recently lowered Stoke Therapeutics' price target to $28 from $29 while maintaining a Buy rating. Shrader's decision is based on the company's 36-month data for Zorevunersen, which demonstrated impressive seizure reductions, even for patients who started with sub-optimal loading doses. This strong endorsement of the treatment's efficacy is a significant factor in the analyst's reassessment [3].

Stoke Therapeutics has been making significant strides in its clinical trials for Zorevunersen, an antisense oligonucleotide designed to boost the expression of the healthy SCN1A gene. The company's global Phase III EMPEROR trial, which began in August 2025, aims to enroll approximately 170 patients aged 2-18 years across the U.S., UK, Europe, and Japan [1]. The trial's primary endpoint is the reduction in major motor seizure frequency, with secondary outcomes assessing improvements in behavior and cognition [1].

The company's Q2 2025 business update highlighted the progress of its pipeline, including the Phase 3 trial of Zorevunersen and the Phase 1 study of STK-002 for Autosomal Dominant Optic Atrophy (ADOA) [3]. The Q2 update also underscored the financial strength of the company, supported by its collaboration with Biogen and recent key leadership hires [3].

Stoke Therapeutics' CEO Edward Kaye stepped down in March 2025, with Ian F. Smith appointed as interim CEO and Arthur Tzianabos as interim executive chairman [2]. The company's focus on expanding its pipeline and clinical capabilities is evident in its recent initiatives, including the initiation of the ADOA Phase 1 study in the UK [3].

The positive data from the 36-month open-label extension studies of Zorevunersen, which showed durable reductions in seizures and improvements in cognition and behavior, has been a significant driver for the analyst's reassessment [3]. Shrader's lowered price target reflects the market's growing confidence in the potential of Zorevunersen as a disease-modifying therapy for Dravet syndrome.

References:
[1] https://www.pharmiweb.com/pwtoday-story/stoke-therapeutics-launches-global-phase-iii-trial-of-zorevunersen-for-dravet-syndrome
[2] https://www.marketscreener.com/news/stoke-therapeutics-reports-impressive-data-for-severe-epilepsy-treatment-wedbush-says-ce7c51dbd089f224
[3] https://www.investing.com/news/company-news/stoke-therapeutics-q2-2025-slides-phase-3-dravet-trial-underway-adoa-program-advances-93CH-4186325